<info type="DiseaseOrPhenotypicFeature">Gene polymorphisms</info> implicated in influencing susceptibility to <info type="DiseaseOrPhenotypicFeature">venous and arterial thromboembolism</info>: frequency distribution in a healthy <info type="OrganismTaxon">German</info> population.

Evolvement and progression of <info type="DiseaseOrPhenotypicFeature">cardiovascular diseases</info> affecting the <info type="DiseaseOrPhenotypicFeature">venous</info> and <info type="DiseaseOrPhenotypicFeature">arterial system</info> are influenced by a multitude of environmental and hereditary factors. Many of these hereditary factors consist of defined <info type="GeneOrGeneProduct">gene polymorphisms</info>, such as <info type="SequenceVariant">single nucleotide polymorphisms (SNPs)</info> or <info type="SequenceVariant">insertion-deletion polymorphisms</info>, which directly or indirectly affect the <info type="DiseaseOrPhenotypicFeature">hemostatic system</info>. The frequencies of individual <info type="GeneOrGeneProduct">hemostatic gene polymorphisms</info> in different normal populations are well defined. However, descriptions of patterns of genetic variability of a larger extent of different factors of hereditary <info type="DiseaseOrPhenotypicFeature">hypercoagulability</info> in single populations are scarce. The aim of this study was i) to give a detailed description of the frequencies of factors of hereditary <info type="DiseaseOrPhenotypicFeature">thrombophilia</info> and their combinations in a <info type="OrganismTaxon">German</info> population (n = 282) and ii) to compare their distributions with those reported for other regions. Variants of <info type="GeneOrGeneProduct">coagulation factors</info> [<info type="GeneOrGeneProduct">factor V 1691G>A (factor V Leiden)</info>, <info type="GeneOrGeneProduct">factor V 4070A>G (factor V HR2 haplotype)</info>, <info type="GeneOrGeneProduct">factor VII Arg353Gln</info>, <info type="GeneOrGeneProduct">factor XIII Val34Leu</info>, <info type="SequenceVariant">beta-fibrinogen -455G>A</info>, <info type="SequenceVariant">prothrombin 20210G>A</info>], <info type="GeneOrGeneProduct">coagulation inhibitors</info> [<info type="GeneOrGeneProduct">tissue factor pathway inhibitor 536C>T</info>, <info type="GeneOrGeneProduct">thrombomodulin 127G>A</info>], <info type="GeneOrGeneProduct">fibrinolytic factors</info> [<info type="GeneOrGeneProduct">angiotensin converting enzyme intron 16 insertion/deletion</info>, <info type="SequenceVariant">factor VII-activating protease 1601G>A (FSAP Marburg I)</info>, <info type="SequenceVariant">plasminogen activator inhibitor 1-675 insertion/deletion (5G/4G)</info>, <info type="GeneOrGeneProduct">tissue plasminogen activator intron h deletion/insertion</info>], and other factors implicated in influencing susceptibility to <info type="DiseaseOrPhenotypicFeature">thromboembolic diseases</info> [<info type="GeneOrGeneProduct">apolipoprotein E2/E3/E4</info>, <info type="GeneOrGeneProduct">glycoprotein Ia 807C>T</info>, <info type="SequenceVariant">methylenetetrahydrofolate reductase 677C>T</info>] were included. The distribution of <info type="GeneOrGeneProduct">glycoprotein Ia 807C>T</info> deviated significantly from the <info type="GeneOrGeneProduct">Hardy-Weinberg equilibrium</info>, and a comparison with previously published data indicates marked region and ethnicity dependent differences in the genotype distributions of some other factors.